



Laboratory of Experimental Oncology and preclinical models



General description of the activities

Use of in vitro cellular models and mouse models for understanding the molecular mechanisms of tumorigenesis and for the validation of potential therapeutic targets.

Role	Name	Position	E-mail	Publications	Keywords
Lab head	Prof. Enrico De Smaele	Full professor	Enrico.desmaele@uniroma1.it	https://pubmed.ncbi.nlm.nih.gov/?term=de+smaele+e&sort=date&size=50	Cancer, Medulloblastoma, Hh pathway, NF-kappaB, KCASH, KCTD1, KCTD21
Lab members	Prof. Marta Moretti	Tenure Track Researcher	Marta.moretti@uniroma1.it	https://orcid.org/0000-0003-4705-6442	DNA methylation microRNAs Hedgehog pathway, CRC
	Dr. Fabio Bordini	Post-doc	Fabio.bordin@uniroma1.it	https://pubmed.ncbi.nlm.nih.gov/?term=fabio+bordin&sort=date&size=50	Ubiquitination, neural development SMURF1 and SMURF2, Gli1
	Dr. Adriano Apostolico	PhD student	Adriano.apostolico@uniroma1.it	https://pubmed.ncbi.nlm.nih.gov/?term=adriano+apostolico&sort=date&size=50	Neural development, hedgehog inhibitors
	Dr Faranak Taj Mir	PhD student	Faranak.tajmir@uniroma1.it	https://www.scopus.com/authid/detail.uri?authorId=57214780465	miRNAs, hedgehog pathway, KCASH2
	Dr Sara Bellardinelli	PhD student	Sara.bellardinelli@uniroma1.it	https://pubmed.ncbi.nlm.nih.gov/?term=bellardinelli+s&sort=date&size=50	Immune system, KCTD1, KCASH2, Hedgehog pathway
	Dr Gloria Terriaca	PhD student	Gloria.terriaca@uniroma1.it	https://pubmed.ncbi.nlm.nih.gov/?term=terriaca+g&sort=date&size=50	CRC models, Hedgehog pathway, KCASH2

Previous and current research

The main research activities can be subdivided in two major topics:

1) Study of the mechanisms which regulate the potentially oncogenic Hedgehog (Hh) pathway in cerebellum and in medulloblastoma, and search for potential therapeutic targets:

-Identification of KCTD11, a new modulator of the Hh pathway, and characterization of a new family of Hedgehog modulators (KCTD11/KCASH1, KCTD21/KCASH2 and KCTD6/KCASH3).

-Identification of novel Hedgehog target genes (Nhlh1 and Insm1), involved in cerebellar development and tumorigenesis;

-Analysis of miRNAs expression during cerebellar development and in medulloblastoma. Use of miRNAs expression profiling for classification of medulloblastoma subtypes; identification of miRNAs targeting the Hedgehog pathway;

- identification and characterization of miRNAs involved in Hedgehog modulation and in cancer cell stemness;

- Identification of miRNAs involved in modulation of KCASH2 expression;

- Identification of new KCASH2 interactors: KCTD15 and KCTD1 as positive modulators of KCASH2 protein stability;

Generation and characterization of the KCASH2 KO mouse model: the role of KCASH2 in cerebellar development, in mouse fertility and in tumorigenesis *in vivo*;

Study of the role of KCASH2 in the modulation of cell cycle and chromosomal instability/aneuploidy.

Study of KCASH2 promoter and analysis of its transcriptional modulators.

2) Study on the role played by the transcription factor NF- κ B in cell survival and cancer:

- characterization of the novel antiapoptotic gene Gadd45 β , regulated by NF- κ B;

- development of therapeutic molecules able to target Gadd45 β ;

- role of ROS in the regulation of apoptosis by NF- κ B, and identification of the gene FHC involved in this regulation;

- role of NF- κ B in the control of energy homeostasis by regulation of mitochondrial respiration;

Selected Publications

1. Lospinoso Severini L, ... De Smaele E, et al., *Cell Death Differ*. 2024 Feb;31(2):170-187. doi: 10.1038/s41418-023-01246-6.
2. Di Fiore A, Bellardinelli S, ... Moretti M, De Smaele E.. *Neoplasia*. 2023 Sep;43:100926. doi: 10.1016/j.neo.2023.100926.
3. Angrisani A, Di Fiore A, ... Moretti M, De Smaele E. *Front Cell Dev Biol*. 2021 Apr 8;9:638508. doi:10.3389/fcell.2021.638508.
4. Akman M, Belisario DC, ... De Smaele E, Riganti C. *J Exp Clin Cancer Res*. 2021 Jan 11;40(1):28. doi: 10.1186/s13046-020-01824-3.
5. -Coni S, ... De Smaele E, et al., *Cell Death Dis*. 2020 Dec 10;11(12):1045. doi: 10.1038/s41419-020-03174-6.
6. Spiombi E, Angrisani A, ... De Smaele E. *Oncogenesis*. 2019 Nov 4;8(11):64. doi: 10.1038/s41389-019-0175-6.
7. Bufalieri F, Infante P, De Smaele E, et al., *Nat Commun*. 2019 Jul 24;10(1):3304. doi: 10.1038/s41467-019-11093-0.
8. Infante P, ... De Smaele E, et al., *Nat Commun*. 2018 Mar 7;9(1):976. doi: 10.1038/s41467-018-03339-0.
9. D'Amico D, Antonucci L,L, De Smaele E, et al., *Dev Cell*. 2015 Oct 12;35(1):21-35. doi: 10.1016/j.devcel.2015.09.008.
10. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, et al., *Nature Cell Biol*. 2011; 13:1272-9.
11. De Smaele E, et al., *Neoplasia*. 2011; 13:374-85.
12. Canettieri G, Di Marcotullio L, Greco A, Coni S, Antonucci L, Infante P, Pietrosanti L, De Smaele E, et al., *Nature Cell Biol*. 2010; 12:132-42.
13. Ferretti E*, De Smaele E*, et al., *Int J Cancer*. 2009; 124:568-77. *Equal contributors.
14. -Ferretti E*, De Smaele E*, et al., *EMBO J*. 2008; 27:2616-27. *Equal contributors.
15. De Smaele E et al., *Neoplasia*, 2008; 10:89-98.
16. Di Marcotullio L, Ferretti E, Greco A, De Smaele E, et al., *Nature Cell Biology*. 2006; 8:1415-23.
17. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De Smaele E., et al., *Cell*. 2004; 119:529-42.
18. *Di Marcotullio L., *Ferretti E., *De Smaele E., et al., *Proc Natl Acad Sci U S A*. 2004; 101:10833-8. *equal contributors
19. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, Nguyen DU, Pham CG, Nelsbach AH, Melis T, De Smaele E, et al., *Nature Cell Biology* 2004; 6:146-53.
20. Zazzeroni F, Papa S, De Smaele E, et al., *Nature* 2003, 424:742.
21. De Smaele E., et al., *Nature*. 2001; 414: 308-13.

Most recent grants

- PI of the PRIN 2022 project: "Novel approaches for the characterization and modulation of the oncogenic Sonic Hedgehog pathway in colorectal cancer. Identification of new potential prognostic markers and therapeutic targets." budget: 210'489 €;
- Co-PI and Responsible of La Sapienza's research unit, PRIN 2022 PNRR project P2022LZXNW_002, "Simultaneous inhibition of multiple signaling transduction pathways by drugs combination in poor prognosis tumors" budget 117'000 €;
- 2023-current. PI of the PNRR project PE6, "HEAL ITALIA", Spoke 2 Sapienza "Intelligent Health", (PI) budget 435'169,14 €;
- Years 12/2014 - 12/2015: scientific manager of the project "PON Ricerca e competitività PON01_02464" (New Biotechnological Drugs Active Through The Modulation Of Receptor Activity); approved budget 4'963'000 €. Consorzio PitecnoBio, Catania;

